Correspondence  by unknown
The authors play on the possible confusion between “pretest
likelihood” and “prevalence” of the disease. The global prevalence of
coronary artery disease in their cohort, which does not appear in the
text, is 64% (83 of 130) for $70% diameter stenosis and 72% (94 of
130) for $50% diameter stenosis. Even in the low pretest likelihood
group (,25%, mean 156 6%), coronary artery disease was present on
coronary angiography in 50% of patients.
It is unusual to have such a prevalence of coronary artery disease in
consecutive women referred for stress SPECT, especially when only
18% presented with typical angina, and 33% presented no symptoms
or nonanginal chest pain. This may explain the good performance of
the test, but it is far from everyday clinical practice.
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Reply
We appreciate the interest of Le Guludec and Sarda in our recent
article (1). Detection of coronary artery disease (CAD) by noninvasive
testing has been more difficult in women than men, principally because
symptoms of myocardial ischemia are less specific in women; there is
an increased incidence of false positive ST segment depression on
exercise electrocardiography, and the overall prevalence of CAD is
lower in women (2–5). However, this prevalence approaches the same
level as that in men by age $75 years (5). Of the total of 201 patients
in our study, 71 had a low likelihood of CAD (,10%), and the other
130 underwent angiography. The sensitivity, specificity and predictive
accuracy of adenosine technetium-99m sestamibi single-photon emis-
sion computed tomography (SPECT) was determined in the catheter-
ized group, and the normalcy rate was determined in the low likelihood
group. Of note, the mean age of the catheterized group was 72 6 10
years, and 57% presented with symptoms of angina pectoris (typical or
atypical angina). These patients were unable to perform exercise and
were referred to adenosine myocardial perfusion imaging in a tertiary
care hospital. Thus, the overall prevalence of CAD in this cohort
would be expected to be higher than that in the general population
referred for noninvasive testing in other clinical settings.
Another factor that increases the prevalence of CAD in patients
undergoing catheterization is the inherent referral bias, whereby
patients with positive scan results are preferentially selected for
catheterization; the prevalence of CAD in both the high and low
likelihood groups in this study should be higher than would be
expected by the prescan likelihood of disease (6). Of 22 patients with
a relatively low prescan likelihood of CAD (,25%) and who under-
went catheterization, the prevalence of CAD ($50% diameter steno-
sis) was 50%. With respect to 71 patients with a low likelihood of CAD
(,10%), on average, by likelihood analysis, 10% (or 7 patients) would
be expected to have CAD. Thus, the overall prevalence of CAD in a
total of 93 patients with ,25% likelihood of CAD could be estimated
at 18 (19%) of 93, appropriate for a group of consecutive women with
this relatively low likelihood of CAD referred for stress nuclear
SPECT. In our catheterized group, the overall prescan likelihood of
CAD was 59 6 30%. Because 73% (95 of 130) had abnormal scan
results, the postscan likelihood of CAD was much higher at 706 36%,
closely approximating the prevalence observed in our catheterized
group of 72% (94 of 130) ($50% diameter stenosis).
The point raised by Le Guludec and Sarda does bring out an
important limitation to using coronary angiography for validation of
noninvasive test results that has previously been described by our
laboratory (6–9). This problem is difficult to avoid unless studies can
be performed in which all patients undergo catheterization regardless
of test results. Because this is unrealistic, a true reference standard is
difficult. The effect of the referral bias is to overestimate the sensitivity
and underestimate the specificity of a test. For this reason, we have
advocated the use of the low likelihood of coronary disease cohort as
a surrogate for test specificity when referral bias is present (8,9).
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Prediction of Infarction by
Stress Echocardiography
Varga et al. (1) analyzed the value of stress echocardiography to
predict the occurence and site of future myocardial infarction (MI).
The authors concluded that of five future MIs, only two are correctly
identified with respect to site; another occurs in a patient with a
previously positive test result, but the vascular territory is different
from the previously identified ischemic area and the remaining two
MIs occur in patients with previously negative stress test results.
Therefore the majority of spontaneous coronary occlusions leading to
MI are unheralded by induced ischemia.
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In their analysis, the authors combined the results of two funda-
mentally different tests: dipyridamole echocardiography (DE) and
dobutamine stress echocardiography (DSE) and justify this by stating
that it has been made clear by a previous study from their group that
the two tests have “virtually identical diagnostic accuracy” (2). How-
ever, the cited study is a comparison in different patients of the two
stress modalities with the addition of atropine, whereas (although not
stated in the Methods section), the patients in the present study (1)
underwent DE without addition of atropine. Several studies (3)
comparing DE without addition of atropine and DSE in the same
patients have shown that the sensitivity for detection of coronary
disease is greater with DSE. As a result, the sensitivity of DSE (13
[76%] of 17) for a future MI tended to be better than that for DE (28
[53%] of 53). This tendency in favor of DSE is in agreement with a
recently published report (4) comparing the prognostic value of DSE
with that of adenosine echocardiography. Additionally, in patients with
ischemia during the test, the ischemia–infarction localization match
tended to be better for DSE (12 [92%] of 13) than for DE (20 [71%]
of 28).
In sharp contrast to the conclusions of the authors, the conclusions
of this study should be the following:
1. The majority of patients with a future MI had positive DSE results.
2. In virtually all patients with dobutamine-induced wall motion
abnormalities, a subsequent MI developed at the site of these
inducible wall motion abnormalities.
3. DSE seems to be more sensitive in predicting MI and more capable
of predicting the localization of this MI than DE.
Furthermore, it would be of great interest to know how many
patients of the total study group had ischemia on DE and DSE. If these
data are available, it would be interesting to know what the specificities
and predictive values of the respective tests were.
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Reply
We thank Geleijnse and Fioretti for their thoughtful comments on our
report. They question the opportunity of pooling together results
obtained from two different tests (dipyridamole and dobutamine–
atropine). In fact, the latter has a higher sensitivity for single-vessel
disease and the former a higher specificity (1), with a similar overall
accuracy of these two “fundamentally different” stress tests, which
happen to have an 80% concordance in detecting the presence and
location of stress-induced dysfunction (1). On the basis of the un-
proved assumption that higher sensitivity (but lower specificity) for
coronary artery disease could translate into greater prognostic power,
the authors calculate that dobutamine–atropine would have a higher
“sensitivity” for predicting reinfarction. Unfortunately, in our study
neither the selection criteria nor the sample size were adequate to
address this point because not all patients with myocardial infarction at
follow-up were selected, but only those with follow-up rest echocar-
diographic information available. This makes calculations of “sensitiv-
ity” (with no information on specificity) a perilous statistical (and
logical) somersault.
Geleijnse and Fioretti want to know whether stress-induced isch-
emia can predict reinfarction. Pharmacologic stress echocardiography
with dipyridamole can predict cardiac death much more strongly than
nonfatal reinfarction, which can be predicted with a relative risk of;2,
whereas the relative risk for death is ;4 (2). Regarding dobutamine–
atropine, in an updated preliminary analysis of the Echocardiography
Dobutamine International Cooperative study, nonfatal myocardial
infarction occurred in 11 of 436 patients with positive tests for
myocardial ischemia and in 13 of 342 patients with negative tests (2.5%
vs. 4%, p 5 NS), whereas peak wall motion score index was a
significant predictor of cardiac death (3). It seems that what is best for
diagnosis is not necessarily best for prognosis: More aggressive dosing
(e.g., combining atropine with dipyridamole or dobutamine) can
optimize the diagnostic performance for minor forms of coronary
artery disease, but it is also likely to increase the probability of
diagnosing more prognostically futile forms of the disease. Unfortu-
nately, “there are more things on heaven and earth [in human coronary
arteries], Horatio [Marcel and Paolo] that can be dreamt of in our
[pharmacologic stress echocardiographic] philosophy.” Plaque rup-
ture, inflammation and embolization are largely independent of plaque
size, which limits coronary flow reserve and determines pharmacologic
stress echocardiographic results. Vulnerable plaques are often angio-
graphically invisible, and a significant number of the disruption
episodes that precipitate infarction occur in coronary arteries that
were normal or mildly stenotic on a previous angiogram (4)—and to
recognize these plaques is asking too much even for third-generation
(atropine) stress echocardiographic testing. In addition, for any given
angiographic stenosis severity, a complex plaque morphology—more
prone to occlusion than a coronary stenosis with simple morpholo-
gy—is more likely to be associated with positivity on dipyridamole than
dobutamine–atropine stress testing (5–7).
To pretend to be able to see everything (all events) by stress
echocardiography is the best way to support skeptics pretending that
stress echocardiography can see nothing. In the real world, even the
“best” (i.e., most cost-effective) tests have their physiologic scotoma
(8), a blind spot that is tightly linked to the underlying physiologic
mechanisms of stress echocardiographic positivity.
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